Nasdaq:LTRN
Lantern Pharma Inc.
A clinical-stage biopharma firm dedicated to advancing innovative cancer and immune system therapies through strategic asset development and potential partnerships.
Key Metrics
Investment Thesis
Bull Case
Lantern Pharma offers high-risk, high-reward potential if any of its clinical candidates achieve regulatory approval and demonstrate robust market demand in the oncology space. The company's focus on unmet needs positions it for significant value creation upon successful product launches, potentially generating substantial future revenues from orphan drug exclusivity periods. Current low valuation relative to potential pipeline success could provide an attractive entry point for investors with a long-term horizon.
Bear Case
The absence of commercial revenue and a growing annual net loss create severe financial sustainability concerns that may lead to dilution or bankruptcy before any product launch. High cash burn coupled with limited liquid assets suggests the company may struggle to fund operations without favorable market conditions for fundraising. The binary nature of biotech investments poses extreme downside risk, where clinical trial failures could render current equity worthless.
About Lantern Pharma Inc.
Lantern Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs, primarily serving the global oncology and immunology markets. The company leverages proprietary drug candidates to address critical patient populations where current treatment options are limited or non-existent.
Analysis
Management Discussion
The company reported a net loss of $20.8M in 2024, driven by substantial research and development expenditures totaling $16.1M and operating expenses of $22.2M as it advances its clinical pipeline. Despite negative cash flow from operations, the firm maintained a positive cash position through financing inflows of $66.7M, though net cash decreased by $14.4M due to significant investing outflows. The widening deficit in retained earnings and increasing annual losses indicate that capital markets support is essential to sustain current development activities.
Industry Overview
The global biopharmaceutical sector is characterized by intense competition, prolonged development timelines, and high regulatory hurdles that separate promising candidates from commercial products. Companies in this space often require billions in capital to bring a single therapy to market while facing strict scrutiny from agencies like the FDA. Success depends on delivering differentiated scientific breakthroughs that can navigate complex clinical pathways and secure favorable reimbursement rates.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $14.4M | $17.9M | $22.2M |
| Operating Income | $-14.4M | $-17.9M | $-22.2M |
| R&D | $8.6M | $11.9M | $16.1M |
| G&A | $5.8M | $6.0M | $6.1M |
| Stock-Based Comp | $1.2M | $1.1M | $652.0K |
| D&A | $10.1K | $14.6K | $17.3K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | $204.4K | $765.4K | $742.4K |
| Pre-Tax Income | $-14.4M | $-17.9M | $-22.2M |
| Income Tax | $-172.8K | $-1.9M | $-1.4M |
| Continuing Ops | $-14.3M | $-16.0M | $-20.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-14.3M | $-16.0M | $-20.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-14.3M | $-16.0M | $-20.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $58.7M | $43.3M | $25.2M |
| Cash & Equivalents | $37.2M | $21.9M | $7.5M |
| Marketable Securities | $18.0M | $19.4M | $16.5M |
| Prepaid Expenses | $3.0M | $2.0M | $1.2M |
| Other Current Assets | $541.2K | $0 | $0 |
| Long-Term Assets | $113.6K | $306.3K | $324.2K |
| PP&E (Net) | $48.0K | $52.1K | $47.4K |
| Operating Leases | $47.7K | $228.3K | $240.0K |
| Other LT Assets | $17.9K | $25.9K | $36.7K |
| Total Assets | $58.8M | $43.6M | $25.6M |
| Current Liabilities | $2.8M | $2.7M | $4.3M |
| Current Leases | $52.9K | $173.0K | $190.8K |
| Other Current Liab | $2.7M | $2.5M | $4.1M |
| Long-Term Liabilities | $0 | $61.5K | $52.8K |
| LT Operating Leases | — | $61.5K | $52.8K |
| Other LT Liab | — | $0 | $0 |
| Total Liabilities | $2.8M | $2.7M | $4.4M |
| Shareholders' Equity | $56.0M | $40.9M | $21.2M |
| Paid-In Capital | $95.7M | $96.3M | $97.1M |
| Retained Earnings | $-39.3M | $-55.2M | $-76.0M |
| AOCI | $-371.4K | $-107.5K | $154.0K |
| Total L&E | $58.8M | $43.6M | $25.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-14.3M | $-16.0M | $-20.8M |
| Non-Cash Adjustments | $36.7K | $2.9M | $2.3M |
| Working Capital Changes | $1.5M | $-1.3M | $693.3K |
| Cash from Operations | $-12.8M | $-14.3M | $-17.8M |
| Capital Expenditures | $27.8K | $18.7K | $12.6K |
| Cash from Investing | $179.3K | $-930.2K | $3.4M |
| Share Buybacks | $2.5M | $500.0K | — |
| Cash from Financing | $-2.2M | $-500.0K | $66.7K |
| FX Effect | $-10.6K | $-28.5K | $-49.5K |
| Net Change in Cash | $-14.8M | $-15.8M | $-14.4M |
| Beginning Cash | $52.5M | $37.7M | $21.9M |
| Ending Cash | $37.7M | $21.9M | $7.5M |
Frequently Asked Questions
How does Lantern Pharma Inc. make money?
The company operates primarily through a single clinical development segment focused on oncology pipelines, supported by general administrative functions. Revenue is currently derived from financing activities, including stock issuance and strategic collaborations, rather than commercial product sales, as the firm remains in the pre-revenue stage of drug development.
What are the main risks for LTRN?
Complete dependence on successful outcomes in upcoming clinical trials, with any failure resulting in total loss of invested capital and stock value. Significant cash burn rate of approximately $21M annually with limited existing cash reserves, creating an urgent need for additional fundraising or strategic partnerships. Lack of current product revenue leaves the company vulnerable to dilution from equity offerings if external funding markets tighten. Regulatory approval uncertainties for novel mechanisms of action could delay market entry indefinitely.
What is LTRN's competitive advantage?
First-mover potential in novel therapeutic modalities targeting specific unmet oncology needs that current market solutions cannot address. Access to a highly skilled internal research team capable of advancing multiple candidates through clinical trials efficiently. Strategic flexibility provided by a lean balance sheet allowing for targeted acquisitions or licensing deals without immediate commercial pressure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.